KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Convertible Debt (2016 - 2025)

Biomarin Pharmaceutical's Convertible Debt history spans 17 years, with the latest figure at $597.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Convertible Debt changed 0.34% year-over-year to $597.2 million, compared with a TTM value of $597.2 million through Dec 2025, changed 0.34%, and an annual FY2025 reading of $597.2 million, changed 0.34% over the prior year.
  • Convertible Debt for Q4 2025 was $597.2 million at Biomarin Pharmaceutical, roughly flat from $596.7 million in the prior quarter.
  • The five-year high for Convertible Debt was $1.1 billion in Q1 2024, with the low at $592.6 million in Q3 2023.
  • Average Convertible Debt over 5 years is $887.1 million, with a median of $1.1 billion recorded in 2021.
  • Year-over-year, Convertible Debt rose 26.21% in 2021 and then crashed 45.25% in 2025.
  • Tracing BMRN's Convertible Debt over 5 years: stood at $1.1 billion in 2021, then grew by 0.37% to $1.1 billion in 2022, then rose by 0.36% to $1.1 billion in 2023, then plummeted by 45.25% to $595.1 million in 2024, then rose by 0.34% to $597.2 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Convertible Debt are $597.2 million (Q4 2025), $596.7 million (Q3 2025), and $596.2 million (Q2 2025).